RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BRAIN Biotech Stock

BRAIN Biotech Equity 2025

BRAIN Biotech Equity

12.62 M EUR

Ticker

BNN.DE

ISIN

DE0005203947

WKN

520394

In 2025, BRAIN Biotech's equity was 12.62 M EUR, a -42.04% increase from the 21.77 M EUR equity in the previous year.

BRAIN Biotech Aktienanalyse

What does BRAIN Biotech do?

The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing BRAIN Biotech's Equity

BRAIN Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BRAIN Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BRAIN Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BRAIN Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BRAIN Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BRAIN Biotech stock

What is the equity of BRAIN Biotech this year?

BRAIN Biotech has equity of 12.62 M EUR this year.

What was the equity of BRAIN Biotech compared to the previous year?

The equity of BRAIN Biotech has increased/decreased by -42.04% decreased compared to the previous year.

What impact does a high equity have on investors of BRAIN Biotech?

A high equity is advantageous for investors of BRAIN Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of BRAIN Biotech?

A low equity can be a risk for investors of BRAIN Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of BRAIN Biotech affect the company?

An increase in equity of BRAIN Biotech can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of BRAIN Biotech affect the company?

A reduction in equity of BRAIN Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of BRAIN Biotech?

Some factors that can affect the equity of BRAIN Biotech include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of BRAIN Biotech so important for investors?

The equity of BRAIN Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can BRAIN Biotech take to change the equity?

To change equity, BRAIN Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does BRAIN Biotech pay?

Over the past 12 months, BRAIN Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BRAIN Biotech is expected to pay a dividend of 0 EUR.

What is the dividend yield of BRAIN Biotech?

The current dividend yield of BRAIN Biotech is .

When does BRAIN Biotech pay dividends?

BRAIN Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BRAIN Biotech?

BRAIN Biotech paid dividends every year for the past 0 years.

What is the dividend of BRAIN Biotech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is BRAIN Biotech located?

BRAIN Biotech is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von BRAIN Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BRAIN Biotech from 6/20/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/20/2025.

When did BRAIN Biotech pay the last dividend?

The last dividend was paid out on 6/20/2025.

What was the dividend of BRAIN Biotech in the year 2024?

In the year 2024, BRAIN Biotech distributed 0 EUR as dividends.

In which currency does BRAIN Biotech pay out the dividend?

The dividends of BRAIN Biotech are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BRAIN Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von BRAIN Biotech

Our stock analysis for BRAIN Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BRAIN Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.